Carl Amilon

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction

Karin Nelander, Maria Lagerström‐Fermér, Carl Amilon et al. · Clinical and Translational Science · 2020 · 44 citations · Full text

Heart Failure, Healthy Subjects, Cardiovascular Pharmacology +16

Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease

Daniel Pettersen, Johan Broddefalk, Hans Emtenäs et al. · Journal of Medicinal Chemistry · 2019 · 37 citations · Full text

Pharmacotherapy, Pharmaceutical Chemistry, Coronary Artery Disease +19

Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator

Fredrik Erlandsson, Muna Albayaty, Ligia Chialda et al. · British Journal of Clinical Pharmacology · 2018 · 27 citations · Full text

Ticagrelor does not impact patient‐reported pain in young adults with sickle cell disease: a multicentre, randomised phase <scp>II</scp> b study

Julie Kanter, Miguel R. Abboud, Banu Kaya et al. · British Journal of Haematology · 2018 · 27 citations · Full text

Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation

Tim R. Eijgenraam, Nienke M. Stege, Vivian Oliveira Nunes Teixeira et al. · International Journal of Molecular Sciences · 2022 · 25 citations · Full text